Navigation Links
Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration
Date:7/22/2009

PHILADELPHIA, July 22 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily Vyvanse(R)( )(lisdexamfetamine dimesylate) CII significantly reduced the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 12 from the first time point measured (1.5 hours) up to the last time point assessed (13 hours) after administration.( ) In this pediatric analog classroom study, treatment with Vyvanse was associated with significant improvement in behavior and attention in children at each time point measured, with improvement at 13 hours after administration.( )

"Pediatric patients may require ADHD symptom improvement both at school and after school,"( )said Sharon Wigal, PhD, lead investigator of the study, clinical professor of pediatrics and director of clinical trials in the Child Development Center at the University of California, Irvine. "These published data are the first to have shown duration of effect of an oral ADHD stimulant in children aged 6 to 12 at 13 hours after administration. Physicians and caregivers who are seeking a long-acting medication that provides ADHD symptom improvement from morning through homework and family time may want to consider this Vyvanse study data."( )

On May 22, 2009, the US Food and Drug Administration (FDA) approved a change to the prescribing information for Vyvanse to include supplemental data that demonstrated significant ADHD symptom improvement in children aged 6 to 12 from the first time point measured (1.5 hours) up to 13 hours postdose. Vyvanse is now the first and only oral ADHD stimulan
'/>"/>

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)..., , SEATTLE, Nov. 20 /PRNewswire-FirstCall...nnounced that the U.S. Food and Drug Administratio...Company,s amended Biologics License Application (B...e response. The FDA has assigned a Prescription D...hich time it will respond to Dendreon,s amended BL...
(Date:11/20/2009)..., , STOCKHOLM, November 20 /PRNewsw...that the European Investment Fund (EIF) has entere... The co-investment fund will be,managed by Karolin...s,portfolio of early-stage pharmaceutical and medi... 26.7 M Euros in the co-investment fund. The agree...
(Date:11/20/2009)... METTLER TOLEDO recently ...ctions Process Optimization Using At-Line Particle...ember 2, 2009. In this webinar, the application o...d to map the design space and optimize a series of...s, flow rates, and roller compaction forces. , ...
(Date:11/19/2009)... , Most people would like to be able to charge th...ckly and not too often. A recent discovery made by...ube-based supercapacitors that could do just this....ysics Letters , Prabhakar Bandaru, a professor in ...gineering, along with graduate student Mark Hoefer...
Breaking Biology Technology:Dendreon Receives FDA Acknowledgement of Complete Response 2Dendreon Receives FDA Acknowledgement of Complete Response 3Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 2Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 3Roller Compaction Process Optimization Using At-Line Particle Characterization 2Nanotube defects equal better energy and storage systems 2
...research may have come up with an explanation as t...d rocks. This explanation could turn out to be the...production techniques with the intent of increasin...arch group at the Nano-Science Center, part of the...n has investigated drill cores collected from Nort...
..., May 11 Sanofi-aventis U.S. announced today that...ma plc the U.S. commercial rights to Oforta(TM) (f... B-cell chronic lymphocytic leukemia (CLL) drug. ... for use as a second-line therapy to treat adults ...to add Oforta to our existing oncology portfolio, ...
...May 11 Pharmasset, Inc. (Nasdaq: VRUS ), a clin...covering, developing, and commercializing novel dr...results and operational highlights for the fiscal ...ults , , Revenues were $1.9 million during the q...on for the quarter ended March 31, 2008 and reflec...
Other Biology Technology:New Danish research shows how oil gets stuck underground 2Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment 2Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment 3Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 2Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 3Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 4Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 5Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 6Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 7Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 8
(Date:11/23/2009)...l Medical Sciences (NIGMS), part of the National I...ion for grants in scientific areas it identified a... grant program to stimulate biomedical research an... Recovery and Reinvestment Act (Recovery Act). , ... a significant impact on a field of biomedical sci...
(Date:11/23/2009)...rector of the Interuniversity Professorship in Law...e University of the Basque Country. The Professors...er experts such as researchers in the fields of mo...ethics. , The Interuniversity Professorship in L...usto and the Basque Country was created in 1993. T...
(Date:11/23/2009)...erman . , Of all global carbon dioxide emiss...where it contributes to global warming. The remain...stems such as forests, grasslands and peat-lands. ...restrial ecosystems is considered one of the main,...ange. However, new greenhouse gas bookkeeping has ...
Breaking Biology News(10 mins):NIGMS invests in scientific Grand Opportunities with Recovery Act funds 2NIGMS invests in scientific Grand Opportunities with Recovery Act funds 3Research and legislation should go hand in hand, as much as possible 2Intensive land management leaves Europe without carbon sinks 2Globus Medical Announces Launch of COALITION 28TM 29 ACDF Spacer System 47604 1Globus Medical Announces Launch of COALITION 28TM 29 ACDF Spacer System 47604 2EXTRA TV Features Tosca Renos Eat Clean Diets Libido Boosting Foods 47600 1EXTRA TV Features Tosca Renos Eat Clean Diets Libido Boosting Foods 47600 2Genomatica Produces Pure BDO From Natural Sugars 12413 1Genomatica Produces Pure BDO From Natural Sugars 12413 2Genomatica Produces Pure BDO From Natural Sugars 12413 3Genomatica Produces Pure BDO From Natural Sugars 12413 4
...ll needs both to build new and to degrade old or d...ntracellular systems work in concert to keep the c...eins. When proteins or peptides mutate, they can p...tracellular environment. In Huntington,s disease (...in gene eventually causes the cell to build up int...
...cientists has announced a major expansion of a lin...s in living organisms. The expansion provides ter... events that occur when a pathogenic or beneficial...events is crucial for developing new interventions...obes while preserving or encouraging the presence ...
...they won,t be able to understand the brain until t...how billions of neurons are interconnected. Now, r...udies have jumped what many believe to be a major ... the connections to a single neuron. , In the Marc...escribe how they modified the deadly rabies virus,...
Other Biology News:Proteasome activator enhances survival of Huntington's disease neuronal model cells 2Uniform language for describing genes of pathogenic and beneficial microbes 2Uniform language for describing genes of pathogenic and beneficial microbes 3Deconstructing brain wiring, one neuron at a time 2Deconstructing brain wiring, one neuron at a time 3
5X StabilCoat Immunoassay Stabilizer from SurModics, Inc.
...llow crystalline solid. PROTECT FROM LIGHT. Useful...response data are not required. Purity: ≥98% b...us systems, preparation of a 10 mM stock in DMSO i... can be added to H 2 O with rapid mixing (e.g. 10 ...
Mouse Anti-Fatty Acid Binding Protein (FABP) Antibody, TRITC (Rhodamine) Conjugated from HyTest Ltd.
Mouse Anti-Rhodopsin Monoclonal Antibody, Unconjugated, Clone RET-P1 from GeneTex
Biology Products: